



Spiration, Inc. Presents Emphysema Device Removal Data at American College of Chest Physicians Annual Conference in Chicago

Unique Design of IBV® Valve System Results in 97 Percent Removal Success Rate

Chicago – Oct. 24, 2007 – A presentation at the American College of Chest Physicians Annual Conference in Chicago today concludes that bronchial valves designed and manufactured by Spiration® for the treatment of patients with severe emphysema can be successfully removed with a high success rate during a minimally invasive bronchoscopic procedure.

Spiration's IBV Valve System is a minimally invasive device under investigation in the U.S. for the treatment of severe emphysema. Although IBV Valves are intended to be permanent implants, they are designed to be removed if necessary. The IBV Valve includes a removal feature, a central rod with an enlarged tip that can be grasped with biopsy forceps passed through a flexible bronchoscope.

"In the event of complication or in cases in which the patient is not benefiting from treatment, it is desirable that devices implanted in an airway be removable," said Douglas E. Wood, M.D., professor and chief of General Thoracic Surgery at the University of Washington in Seattle, the lead author of the analysis. "It is clear that the unique design of Spiration's device does consistently allow for removal in a majority of attempts, enabling a reversal of the procedure. In addition, the anchor design of the IBV Valve resulted in no migration, expectoration or bronchial erosion."

A retrospective analysis was presented using data from the company's U.S. pilot study of 91 patients treated with 609 valves. During the first three months following initial treatment 23 valves were successfully removed and replaced for technical reasons in 17 patients. In the first year following initial treatment an additional 162 valves were successfully removed for clinical reasons, lack of benefit, or patient request in 28 patients. In total, 185 valves were removed in 191 attempts, for an overall valve removal success rate of 97 percent.

Spiration recently announced that the first patients have been enrolled in the company's IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness



data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company's IBV Valve System in the United States for the treatment of patients with severe emphysema.

"We are pleased with our progress to date with the IBV Valve Trial," said Rick Shea, president and CEO, Spiration. "We look forward to completing enrollment in the trial and publishing the results of our work in this exciting investigational area."

For the treatment of emphysema, the IBV Valve System is designed to redirect airflow from diseased portions of the lung to healthier areas. During the minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the bronchial tubes through the mouth or nose) to deploy the small umbrella-shaped valves into the airways of the upper lobes of the lungs.

The system has received CE Mark approval for the treatment of diseased and damaged lung in Europe and is an investigational device in Canada.

About Emphysema

Emphysema, a component of Chronic Obstructive Pulmonary Disease (COPD), is a common, debilitating lung disease with no cure in which the tiny air sacs that make up the lungs (alveoli) are enlarged or destroyed. This impairs the exchange of oxygen and carbon dioxide with the blood, reduces the lungs' ability to exhale air, and is accompanied by coughing and breathing difficulties, initially with exertion and eventually also while at rest. The most common cause of emphysema is an inflammatory reaction to inhaled smoke. Currently available treatments for emphysema are generally palliative and include medications, home oxygen therapy, pulmonary rehabilitation, lung volume reduction surgery and lung transplantation.



About the IBV Valve Trial

Study investigators are actively recruiting patients for the IBV Valve Trial. For information, including trial site locations, please visit www.emphysematrial.com or call (877) 547-8839. Treatment with the investigational IBV Valve System is not appropriate for all patients with emphysema. Some patients treated with the IBV Valve System receive no measurable benefit.

About Spiration, Inc.

Spiration, Inc. is committed to improving quality of life for patients with acute and chronic conditions of the lung through the development of novel therapies. Founded in 1999 in Redmond, Wash., the privately held company is backed by prominent investors including Three Arch Partners, New Enterprise Associates, Versant Ventures, Sprout Group, InterWest Partners, Investor Growth Capital, GE Capital, Boston Scientific Corporation and Olympus Medical Systems Corporation. For more information, visit the company's website at www.spiration.com.

#

CAUTION – Investigational Device. Limited by Federal (or U.S.) Law to Investigational Use.